FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:65-66 January 7, 1999 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: In the past 15 years, the medical community has seen the publication of reports on large, randomized clinical trials that have had a substantial effect on the practice of medicine. The design, execution, and analysis of these trials is the province of many outstanding investigators, but many such trials are supported by private pharmaceutical houses that have a clear interest in the outcomes. Although the integrity of the investigators ensures that the results have been fairly presented, pharmaceutical support creates the appearance of undue influence by those with a vested interest.

One way to mitigate the appearance . . . [Full Text of this Article]

This article has been cited by other articles:

• Wilhelmus, K. R. (2001). Submission of Data Sets to Journals: Opportunities for Improving Good Research Practice. Arch Ophthalmol 119: 623-623 [Full Text]